- Home
- PPBI vs SWTX Comparison
PPBI vs SWTX Comparison
Compare PPBI & SWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBI
- SWTX
- Stock Information
- Founded
- PPBI 1983
- SWTX 2017
- Country
- PPBI United States
- SWTX United States
- Employees
- PPBI N/A
- SWTX N/A
- Industry
- PPBI Major Banks
- SWTX Biotechnology: Pharmaceutical Preparations
- Sector
- PPBI Finance
- SWTX Health Care
- Exchange
- PPBI Nasdaq
- SWTX Nasdaq
- Market Cap
- PPBI 2.5B
- SWTX 2.2B
- IPO Year
- PPBI 1997
- SWTX 2019
- Fundamental
- Price
- PPBI $27.75
- SWTX $36.45
- Analyst Decision
- PPBI Buy
- SWTX Strong Buy
- Analyst Count
- PPBI 6
- SWTX 5
- Target Price
- PPBI $26.50
- SWTX $65.40
- AVG Volume (30 Days)
- PPBI 587.4K
- SWTX 1.3M
- Earning Date
- PPBI 10-24-2024
- SWTX 11-12-2024
- Dividend Yield
- PPBI 4.76%
- SWTX N/A
- EPS Growth
- PPBI N/A
- SWTX N/A
- EPS
- PPBI N/A
- SWTX N/A
- Revenue
- PPBI $379,785,000.00
- SWTX $135,487,000.00
- Revenue This Year
- PPBI N/A
- SWTX $3,498.68
- Revenue Next Year
- PPBI N/A
- SWTX $98.08
- P/E Ratio
- PPBI N/A
- SWTX N/A
- Revenue Growth
- PPBI N/A
- SWTX N/A
- 52 Week Low
- PPBI $20.52
- SWTX $20.19
- 52 Week High
- PPBI $30.13
- SWTX $53.92
- Technical
- Relative Strength Index (RSI)
- PPBI 57.46
- SWTX 71.38
- Support Level
- PPBI $24.43
- SWTX $29.53
- Resistance Level
- PPBI $29.01
- SWTX $35.26
- Average True Range (ATR)
- PPBI 0.90
- SWTX 1.92
- MACD
- PPBI 0.12
- SWTX 0.74
- Stochastic Oscillator
- PPBI 63.72
- SWTX 87.38
About PPBI Pacific Premier Bancorp Inc
Pacific Premier Bancorp Inc through its subsidiaries, provides banking products and services. It offers cash management, electronic banking services, credit facilities, and retirement accounts, among others.
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.